GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Float Percentage Of Total Shares Outstanding

Xbrane Biopharma AB (OSTO:XBRANE) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 06, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Xbrane Biopharma AB's float shares is 0.00 Mil. Xbrane Biopharma AB's total shares outstanding is 1,529.48 Mil. Xbrane Biopharma AB's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Xbrane Biopharma AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Xbrane Biopharma AB's Institutional Ownership is 3.38%.

Xbrane Biopharma AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Xbrane Biopharma AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/1,529.48
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB (OSTO:XBRANE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
OSTO:DMYD B OSTO:CANTA XSAT:CURAS OSTO:ONCO OSTO:SYNACT OSTO:ITECH OSTO:INIT OSTO:IVACC OSTO:INDEX OSTO:KDEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
7XB:Germany
Address
Retzius vag 8, Solna, SWE, 171 65
Website
https://www.xbrane.com
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (OSTO:XBRANE) Headlines

No Headlines